Real World Outcomes with Idecabtagene Vicleucel ( Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

被引：20

作者：

Sidana, Surbhi ^{[1
]}

Ahmed, Nausheen ^{[2
]}

Akhtar, Othman S. ^{[3
]}

Heim, Michael ^{[4
]}

Brazauskas, Ruta ^{[4
,5
]}

Hansen, Doris K. ^{[6
]}

Ferreri, Christopher ^{[7
]}

Freeman, Ciara Louise L. ^{[8
]}

Afrough, Aimaz ^{[9
]}

Anderson, Larry D., Jr. ^{[10
]}

Dhakal, Binod ^{[11
]}

Dhanda, Devender ^{[12
]}

Gowda, Lohith ^{[13
,14
]}

Hashmi, Hamza ^{[15
]}

Harrison, Melanie ^{[16
]}

Kitali, Amani

Mirza, Sayeef ^{[17
]}

Patel, Jinalben ^{[4
]}

Patwardhan, Pallavi ^{[16
]}

Usmani, Saad Z. ^{[18
]}

Patel, Krina K. ^{[19
]}

Ganguly, Siddhartha ^{[20
,21
]}

Pasquini, Marcelo ^{[4
]}

机构：

[1] Stanford Univ, Stanford, CA USA

[2] Univ Kansas, Canc Ctr, Westwood, KS USA

[3] Moffit Canc Ctr, Tampa, FL USA

[4] Med Coll Wisconsin, CIBMTR R Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI USA

[5] Med Coll Wisconsin, Div Biostat, Inst Hlth & Equ, Milwaukee, WI USA

[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[8] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA

[9] UT SouthWestern Med Ctr, Dallas, TX USA

[10] UT SouthWestern Med Ctr, Myeloma Waldenstroms & Amyloidosis Program, Hematol Malignancies & Cellular Therapy Program, Simmons Comprehens Canc Ctr, Dallas, TX USA

[11] Med Coll Wisconsin, BMT & Cellular Therapy, Div Hematol & Oncol, Dept Med, Milwaukee, WI USA

[12] Bristol Myers Squibb, Princeton, NJ USA

[13] Yale Canc Ctr, New Haven, CT USA

[14] Yale Sch Med, New Haven, CT USA

[15] Med Univ South Carolina, Charleston, SC USA

[16] Bristol Myers Squibb, Princeton, NJ USA

[17] Yale Sch Med, New Haven, CT USA

[18] Mem Sloan Kettering Canc Ctr, Adult Bone Marrow Transplant Serv, Dept Med, New York, NY USA

[19] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[20] Houston Methodist Hosp, Houston, TX USA

[21] Neal Canc Ctr, Houston, TX USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-181762

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[1] Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma
Anderson, Larry D., Jr.
FUTURE ONCOLOGY, 2021, 18 (03) : 277 - 289
[2] Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience.
Hansen, Doris K.
Sidana, Surbhi
Peres, Lauren
Shune, Leyla
Sborov, Douglas W.
Hashmi, Hamza
Kocoglu, Mehmet H.
Atrash, Shebli
Simmons, Gary
Kalariya, Nilesh
Ferreri, Christopher J.
Afrough, Aimaz
Kansagra, Ankit J.
Voorhees, Peter M.
Alsina, Melissa
McGuirk, Joseph
Locke, Frederick L.
Patel, Krina K.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[3] Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
Sanoyan, Dilara Akhoundova
Seipel, Katja
Bacher, Ulrike
Kronig, Marie-Noelle
Porret, Naomi
Wiedemann, Gertrud
Daskalakis, Michael
Pabst, Thomas
BMC CANCER, 2023, 23 (01)
[4] Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
Dilara Akhoundova Sanoyan
Katja Seipel
Ulrike Bacher
Marie-Noelle Kronig
Naomi Porret
Gertrud Wiedemann
Michael Daskalakis
Thomas Pabst
BMC Cancer, 23
[5] Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma
Mancuso, Katia
Barbato, Simona
Talarico, Marco
Tacchetti, Paola
Zamagni, Elena
Cavo, Michele
EXPERT OPINION ON BIOLOGICAL THERAPY, 2025, 25 (01) : 27 - 46
[6] Single-center experience with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma
Sanoyan, D. Akhoundova
Bacher, U.
Kronig, M. -N.
Seipel, K.
Daskalakis, M.
Pabst, T.
SWISS MEDICAL WEEKLY, 2022, 152 : 64S - 64S
[7] Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): US Myeloma CAR T Consortium Real World Experience
Hashmi, Hamza
Hansen, Doris K.
Peres, Lauren C.
Puglianini, Omar Alexis Castaneda
Freeman, Ciara L.
De Avila, Gabriel
Sidana, Surbhi
Shune, Leyla O.
Sborov, Douglas W.
Davis, James
Wagner, Charlotte B.
Kocoglu, M. Hakan
Atrash, Shebli
Voorhees, Peter M.
Simmons, Gary
Ferreri, Christopher J.
Kalariya, Nilesh
Sannareddy, Aishwarya
Dima, Danai
Khouri, Jack
McGuirk, Joseph P.
Locke, Frederick L.
Baz, Rachid C.
Patel, Krina
Alsina, Melissa
BLOOD, 2022, 140 : 4642 - 4645
[8] Bendamustine Lymphodepletion (LD) Prior to Idecabtagene Vicleucel (Ide-cel) Is Associated with Inferior Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)
Ravi, Gayathri
Bal, Susan
Godby, Kelly
Giri, Smith
Hebert, Courtney
Parekh, Binita
Steele, JoAnn
Brown, Jessica
Langley, Kathy
Costa, Luciano
BLOOD, 2023, 142
[9] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.
Anderson, Larry D., Jr.
Munshi, Nikhil C.
Shah, Nina
Jagannath, Sundar
Berdeja, Jesus G.
Lonial, Sagar
Raje, Noopur S.
Siegel, David Samuel DiCapua
Lin, Yi
Oriol, Albert
Moreau, Philippe
Yakoub-Agha, Ibrahim
Delforge, Michel
Petrocca, Fabio
Patel, Payal
Huang, Liping
Campbell, Timothy B.
Hege, Kristen
San-Miguel, Jesus F.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[10] EVALUATION OF HEALTH STATUS IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), CAR T CELL THERAPY AGAINST BCMA
Paula, Rodriguez-Otero
Michel, Delforge
Nina, Shah
Parames-Waran, Hari
Julia, Braverman
Andrew, Trigg
Payal, Patel
Liping, Huang
Kristen, Hege
Sujith, Dhanasiri
HAEMATOLOGICA, 2021, 106 (10) : 287 - 288

← 1 2 3 4 5 →